Dr. Bayraktar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Centermed Görüntüleme Merkezi
Güzelbahçe Sokak 15
Warren, MI 48092
Education & Training
- University of Massachusetts AmherstM.B.A., 2010 - 2012
- University of Massachusetts AmherstM.B.A., 2010 - 2012
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2011
- University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2008 - 2010
- Mount Sinai Medical Center of FloridaResidency, Internal Medicine, 2007 - 2008
- Wayne State University School of MedicineResidency, Internal Medicine, 2005 - 2007
- Hacettepe University FOMClass of 2003
Certifications & Licensure
- OH State Medical License 2024 - 2026
- MA State Medical License 2024 - 2025
- WI State Medical License 2017 - 2025
- WV State Medical License 2020 - 2024
- CO State Medical License 2018 - 2023
- FL State Medical License 2019 - 2023
- TX State Medical License 2010 - 2022
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Annual Meeting Merit Award American Society of Clinical Oncology (ASCO), 2011
- Grant for AACR Molecular Biology in Clinical Oncology Workshop National Institutes of Health (NIH), 2009
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- 135 citationsEffect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.Soley Bayraktar, Leonel F. Hernadez-Aya, Xiudong Lei, Funda Meric-Bernstam, Jennifer K. Litton
Cancer. 2012-03-01 - 77 citationsOutcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsSoley Bayraktar, Angelica M. Gutierrez-Barrera, Diane Liu, Tunc Tasbas, Ugur Akar
Breast Cancer Research and Treatment. 2011-08-10 - 288 citationsCancer prevention with natural compounds.Norleena Gullett, A.R.M. Ruhul Amin, Soley Bayraktar, John M. Pezzuto, Dong M. Shin
Seminars in Oncology. 2010-06-01
Books/Book Chapters
Abstracts/Posters
- Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast CancerBayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F, 47th ASCO Annual Meeting, J Clin Oncol, 1/1/2011
- Prognostic Relevance of Eight Genome Wide Association Studies-identified Single-nucleotide Polymorphisms in Primary Breast CancerBayraktar S, Thompson PA, Yoo SY, Do K, Sahin AA, Arun BK, Bondy ML, Brewster AM, AACR International Conference on Frontiers in Cancer Prevention Research, AACR Cancer Prevention Research, 1/1/2011
- Prevalence of BRCA1 and BRCA2 Mutations in Women with Diagnosed with DCISElsayegh N, Bayraktar S, Gutierrez Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Arun B, 47th ASCO Annual Meeting, J Clin Oncol, 1/1/2011
- Join now to see all
Lectures
- Advances in the Management of BRCA-associated Breast CancersAntalya, Turkey - 3/1/2012
- Prognostic Relevance of Eight Genome Wide Association Studies-identified Single-nucleotide Polymorphisms in Primary Breast CancerBoston, MA - 10/1/2011
- Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast CancerChicago, IL - 6/1/2011
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Turkish, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: